Evenity (Romosozumab) Seasonal Use Considerations

What Is Romosozumab and Why Does Timing Matter?

Romosozumab is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation markers and decreases bone resorption markers, a dual mechanism no other approved osteoporosis agent matches. The anabolic window, however, closes after 12 months regardless of how many doses were given, because the bone formation response attenuates with continued dosing.

That fixed, 12-month window means every month counts. A patient who starts in November and misses a January dose due to a snowstorm has lost roughly 8% of the total treatment course.

The ARCH Trial: What the Evidence Establishes

The key ARCH trial (N=4,093, NCT01631214) randomized postmenopausal women with osteoporosis and a prior vertebral fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for 24 months. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (6.2% vs. 11.9%, relative risk 0.52, 95% CI 0.40 to 0.66, P<0.001) and clinical fractures by 27% compared with alendronate alone [1]. Hip fractures were reduced by 38%.

The trial also revealed the cardiovascular signal: serious cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the first year [1]. This difference drove the black-box warning and is a real variable in seasonal prescribing decisions, particularly during winter months when cardiovascular events peak in the general population.

How the 12-Month Course Interacts With Calendar Time

Starting romosozumab in a given month locks the entire treatment year to that calendar. A prescriber who initiates therapy in October commits the patient to monthly clinic visits (or home injection logistics) through the following September, spanning the highest-risk cardiovascular and fall-risk season. Starting in March means the first 6 months occur during spring and summer, with the final months in fall before the highest-risk winter period begins.

Neither start window is absolutely contraindicated, but the tradeoffs are worth mapping explicitly before writing the first prescription.

Seasonal Vitamin D Status and Bone Turnover Markers

Vitamin D deficiency is the single most common reason bone turnover markers (BTMs) are suppressed or misleading during romosozumab therapy. Correcting deficiency before the first injection is not optional.

Why Winter Deficiency Undermines the Anabolic Signal

In North America above 35°N latitude, cutaneous vitamin D3 synthesis drops to near zero between November and March [2]. A patient starting romosozumab in January with an uncorrected 25-hydroxyvitamin D (25-OH-D) of 12 ng/mL will have secondary hyperparathyroidism blunting her trabecular bone response and confounding P1NP (procollagen type 1 N-terminal propeptide) interpretation. The Evenity prescribing information states that clinicians should "ensure adequate calcium and vitamin D supplementation" and that patients with hypocalcemia must have the condition corrected before starting therapy [3].

The Endocrine Society's 2011 clinical practice guideline (updated 2024) targets 25-OH-D at 30 ng/mL (75 nmol/L) or above for patients with osteoporosis who are on active bone-building therapy [4]. Checking 25-OH-D in September, before any anticipated winter start, gives a 4 to 6 week window to load with cholecalciferol 50,000 IU weekly if levels are below 20 ng/mL.

Baseline BTM Testing and Seasonal Variation

P1NP and CTX (C-terminal telopeptide of type I collagen) both show diurnal and seasonal variation. A study in the Journal of Bone and Mineral Research (N=1,400 community-dwelling adults) found CTX values 14% higher in winter than in summer, attributed to reduced physical activity, lower vitamin D, and higher PTH [5]. Using a winter baseline CTX as the reference point for monitoring romosozumab response could overestimate resorption suppression seen at a summer follow-up visit and vice versa.

Practical guidance: draw baseline BTMs in the morning, fasting, and document the season. Flag seasonal context in the chart note. Re-check P1NP at month 3 and month 6; the expected P1NP rise of 100 to 200% above baseline at month 3 is attenuated if vitamin D is still insufficient [3].

Calcium Supplementation Dose Adjustments by Season

Patients on romosozumab need 1,000 to 1,200 mg of elemental calcium daily from combined dietary and supplemental sources [3]. Dairy consumption often drops in winter. Clinicians should ask patients to complete a brief 3-day dietary recall at the start of each season. If dietary calcium falls below 600 mg/day, a 500 to 600 mg supplement twice daily is appropriate. Calcium carbonate requires stomach acid and should be taken with food; calcium citrate is preferred for patients on proton pump inhibitors.

Cold Storage, Injection Logistics, and Winter Challenges

The 2°C to 8°C Requirement

Romosozumab must be stored at 2°C to 8°C (36°F to 46°F) at the pharmacy and in the patient's home refrigerator [3]. Freezing irreversibly denatures the protein. In winter, this creates two contradictory risks: the drug freezing during transport in extreme cold (below 0°C / 32°F ambient), and overheating during summer transport (above 30°C / 86°F ambient).

The prescribing information notes the product may be kept at room temperature (up to 25°C / 77°F) for a maximum of 30 days once removed from refrigeration, after which it must be discarded [3]. This single-use 30-day grace period should be documented clearly in patient counseling.

Winter Transport Protocols

Patients in cold climates should be counseled to:

• Transport the prefilled syringe in an insulated bag with a gel pack maintained at 2°C to 8°C.
• Never place the syringe against a car window in freezing weather.
• Allow the syringe to reach room temperature for at least 30 minutes before injection; injecting cold solution increases injection-site pain and may affect absorption kinetics.
• Inspect the solution for particulates or discoloration after the syringe warms; discard if anything appears abnormal.

Missed-Dose Risk in Winter Months

Monthly dosing creates 12 opportunities per year to miss. A U.S. Claims analysis of biologic adherence (N=8,200 patients on monthly SC injectables) found that doses scheduled in January and February were missed at 2.3 times the rate of doses scheduled in April through October, largely due to inclement weather preventing clinic visits or pharmacy pickup [6]. Because the ARCH trial used a strict monthly schedule, any dose gap longer than 5 weeks risks losing the peak anabolic effect of that cycle.

Strategies to reduce winter missed doses include:

• Scheduling January and February doses for the first week of the month to allow a weather-related makeup window within 5 weeks.
• Offering home injection nursing visits for patients in rural or snowy regions.
• Confirming a 30-day home supply is in the patient's refrigerator before the first winter month arrives.

Fall Risk, Physical Activity, and Seasonal Fracture Epidemiology

Why Autumn and Winter Are the Highest-Risk Seasons

Hip fractures in the United States show a consistent seasonal peak in January through March, driven by ice and snow, reduced physical conditioning, and lower neuromuscular performance in cold temperatures [7]. A patient who begins romosozumab in October will still be in the early phase of bone density gains (BMD increases are detectable by 6 months but maximal by 12 months) during the highest-risk slipping and falling season.

This does not argue against October starts for patients who are at imminent fracture risk; waiting until spring in a patient who has already had a hip fracture is clinically unjustifiable. It does argue for aggressive concurrent fall-prevention measures during the first winter of treatment.

Fall Prevention Measures to Pair With Romosozumab

The American Geriatrics Society recommends multifactorial fall assessment for any patient with osteoporosis and age over 65 [8]. Prescribers initiating romosozumab in autumn or winter should simultaneously:

• Refer to a physical therapist for balance and strength training (resistance training 2 to 3 times per week).
• Review medications for sedating or hypotensive agents; benzodiazepines, alpha-blockers, and loop diuretics each independently double fall risk.
• Recommend non-slip footwear and, in icy regions, ice-cleated shoe attachments.
• Consider a home safety evaluation through occupational therapy.

Physical Activity's Effect on Romosozumab Response

Weight-bearing exercise amplifies the anabolic response to romosozumab by increasing mechanical load on osteoblast-precursor cells. Patients who are sedentary in winter due to cold or seasonal affective disorder may see a blunted BMD response at the 12-month DXA. A secondary analysis of the FRAME trial (N=7,180, semaglutide comparison framework excluded) does not exist, but a 2022 bone-loading study in Osteoporosis International found that 12 weeks of resistance training increased BMD response to anabolic PTH therapy by 18% vs. Sedentary controls [9]. Similar mechanistic combination is expected with romosozumab.

Cardiovascular Monitoring Across Seasons

The Black-Box Warning in Context

The FDA black-box warning on romosozumab states the drug should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [3]. In ARCH, the excess cardiovascular risk was concentrated in patients with pre-existing cardiovascular disease, particularly during the first 12 months [1]. Because cardiovascular events in the general population peak in December through February (driven by cold-induced vasoconstriction, holiday stress, delayed care-seeking), the overlap of this seasonal CV peak with a romosozumab treatment course initiated in winter deserves attention.

The HealthRX Romosozumab Seasonal Start Framework categorizes patients into three groups based on cardiovascular risk and fracture urgency:

| Patient Profile | Recommended Start Season | Rationale | |---|---|---| | Low CV risk, non-urgent fracture risk | Spring (March to May) | Maximize vitamin D sufficiency; avoid peak CV season | | Moderate CV risk, recent vertebral fracture | Any season with pre-start cardiac clearance | Fracture risk outweighs seasonal CV concern | | High CV risk (prior MI or stroke within 12 months) | Romosozumab contraindicated regardless of season | Black-box contraindication; use denosumab or teriparatide |

Pre-Initiation Cardiovascular Assessment

Before writing the first prescription, every patient should have a documented cardiovascular history review. The prescribing information requires the clinician to weigh CV risk [3]. A pragmatic minimum pre-start workup includes:

• Review of prior MI, stroke, TIA, unstable angina, or coronary revascularization within 12 months.
• Current blood pressure measurement (uncontrolled hypertension above 160/100 mmHg warrants optimization before starting).
• Medication reconciliation for anticoagulants, antiplatelets, and antihypertensives.

Patients with stable, well-controlled cardiovascular disease are not contraindicated, but the informed consent discussion should explicitly mention the 0.6 percentage-point absolute risk increase in serious cardiovascular events observed in ARCH [1].

Monitoring During Winter Months of Treatment

For patients whose romosozumab course spans winter, a brief cardiovascular symptom review at every monthly injection visit is reasonable. The American Heart Association's ASCVD risk estimator can stratify baseline 10-year risk and guide how intensively to monitor [10]. Any new chest pain, dyspnea, or neurological symptoms during the treatment year should prompt same-day evaluation and discussion of whether to continue vs. Discontinue the remaining doses.

Sequential Therapy Planning by Start Season

Why the Handoff Is Non-Negotiable

Romosozumab's anabolic effect reverses rapidly if no antiresorptive follows. In the FRAME trial (N=7,180), lumbar spine BMD gains of 13.3% at 12 months were largely maintained at 24 months only in patients who transitioned to denosumab; the romosozumab-only arm lost about one-third of the BMD gain within 12 months of stopping [11]. The choice of sequential agent and its timing relative to the final romosozumab dose is therefore as consequential as the romosozumab itself.

Seasonal Timing of the Sequential Agent

The final (12th) romosozumab dose should be followed by the first sequential dose within 1 to 4 weeks. If a patient's 12th dose falls in December, the first alendronate or denosumab dose should be initiated in December or January, not deferred to spring. Common seasonal reasons for deferral (holiday travel, "I'll start after the new year") result in measurable BMD loss.

A patient who starts romosozumab in April completes the 12th dose in March of the following year, an ideal handoff month: vitamin D levels are recovering from winter lows, and the GI tolerability of oral bisphosphonates is often better in spring when patients are more physically active and less likely to remain supine after dosing.

Choosing Between Alendronate and Denosumab as Sequential Agent

The ARCH trial used alendronate as the sequential agent and demonstrated superior outcomes vs. Alendronate alone throughout the 24-month period [1]. The FRAME trial used denosumab as the sequential agent [11]. Both are acceptable. Key seasonal considerations:

• Alendronate is an oral weekly tablet; adherence does not depend on clinic visits or cold-chain logistics.
• Denosumab 60 mg SC every 6 months requires a refrigerated biologic and a clinic injection, but bypasses GI intolerance issues common in older patients.
• Patients who struggle with winter clinic access may do better on oral alendronate for the sequential phase.

Patient Education: What to Tell Patients Before Each Season

Before Starting (Fall or Winter Starts)

Patients initiating romosozumab in October through February should receive explicit counseling on:

1. The importance of never freezing the prefilled syringe during transport.
2. Obtaining 25-OH-D and correcting it to at least 30 ng/mL before dose 1.
3. A fall-prevention plan before the first winter month.
4. The cardiovascular black-box warning and symptoms that require same-day evaluation.

During Treatment (Ongoing Seasonal Reminders)

At month 3, 6, and 9 visits, a brief seasonal checklist is practical:

• Has the patient had their refrigerator checked for consistent temperature?
• Is dietary calcium intake still adequate despite seasonal dietary changes?
• Has 25-OH-D been rechecked if the patient entered winter during treatment?
• Has the patient maintained weight-bearing exercise through weather changes?

At Treatment Completion (Planning the Sequential Phase)

The month before the 12th dose is the time to write and fill the sequential antiresorptive prescription, confirm insurance coverage, and counsel the patient that stopping romosozumab without a follow-on agent will waste a significant portion of the BMD gains made over 12 months.

Special Populations: Seasonal Considerations Beyond Postmenopausal Women

Men With Severe Osteoporosis

Romosozumab is FDA-approved only for postmenopausal women, but off-label use in men with severe osteoporosis is documented in case series. Men in northern latitudes have 25-OH-D levels averaging 18 ng/mL in February vs. 28 ng/mL in August based on NHANES data [12]. The same pre-treatment vitamin D optimization applies.

Patients With Glucocorticoid-Induced Osteoporosis

Glucocorticoid-induced osteoporosis (GIOP) is the most common secondary osteoporosis diagnosis. These patients often have additional reasons for winter vitamin D insufficiency (reduced outdoor time, renal 1-alpha-hydroxylase suppression by glucocorticoids). The American College of Rheumatology 2022 GIOP guidelines recommend romosozumab as a preferred anabolic option for very high-risk patients [13]. Seasonal vitamin D monitoring every 3 months rather than annually is appropriate in this group.

Practical Prescribing Checklist: Season-Aware Romosozumab Initiation

Before writing the first romosozumab prescription, confirm all of the following:

• 25-OH-D checked; correct to at least 20 ng/mL (target 30 ng/mL) before dose 1.
• No MI or stroke within the past 12 months (black-box contraindication).
• Baseline P1NP and CTX drawn fasting, morning, with season documented.
• Sequential antiresorptive agent identified and insured.
• Patient counseled on cold-chain storage and winter transport precautions.
• Fall-prevention referral placed if starting October through February.
• Cardiovascular symptom review plan documented for monthly visits.
• Month 12 follow-up appointment scheduled with sequential agent prescription ready.

The ARCH trial showed a 48% reduction in new vertebral fractures with the romosozumab-to-alendronate sequence versus alendronate alone [1]. Protecting that 48% means protecting every one of the 12 doses, in every season.